Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905811 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Terazosin for Parkinson's Disease
A Phase 1 study of Parkinson Disease, sponsored by Jordan Schultz.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03905811: Completed Phase 1 study of Parkinson Disease, sponsored by Jordan Schultz.
NCT03905811 is a Phase 1 study of Parkinson Disease that has completed, run by Jordan Schultz. The registered enrollment target is 13 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03905811, a Phase 1 study of Parkinson Disease, has completed, sponsored by Jordan Schultz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.
Primary Outcome
All patient-reported adverse events will be determine to be related to the study intervention by the site investigator.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Terazosin 5 MG
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 1 |
What the finished NCT03905811 record still lists
NCT03905811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03905811 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT03905811 about?
NCT03905811 is a clinical study titled "A Pilot Study of Terazosin for Parkinson's Disease". The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.
What is the current status of trial NCT03905811?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-09-24. Estimated completion is 2020-11-18.
What conditions does trial NCT03905811 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT03905811?
The interventions under investigation include: Placebo oral capsule (DRUG), Terazosin 5 MG (DRUG).
Who is sponsoring clinical trial NCT03905811?
This trial is sponsored by Jordan Schultz, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03905811 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03905811's enrollment target sits among peer trials
13 267th of 297 higher than 31 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI